In Ewing sarcoma, however, EWS/FLI displays a “gain-of-function” in its ability to also bind ‘GGAA’-containing microsatellite (repeat) regions to regulate some of its targets, such as key oncogenic target NR0B1 [8,9]. Here, FLII is linked to Ewing sarcoma.